
Fausto Roila

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4318168/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Inflamed Tumor Phenotype as Predictor of Long-Term Response to Pembrolizumab in an EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patient with Acquired Resistance to Afatinib: a Case Report and Review of the Literature. Oncology and Therapy, 2022, 10, 291-300.	1.0	1
2	Molecular Profiling and Novel Therapeutic Strategies for Mucosal Melanoma: A Comprehensive Review. International Journal of Molecular Sciences, 2022, 23, 147.	1.8	8
3	Supportive Care: Low Cost, High Value. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, 240-250.	1.8	6
4	Upfront pembrolizumab as an effective treatment start in patients with PD-L1 ≥ 50% non-oncogene addicted non-small cell lung cancer and asymptomatic brain metastases: an exploratory analysis. Clinical and Translational Oncology, 2021, 23, 1818-1826.	1.2	11
5	Sensitivity to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations. Genes, 2021, 12, 679.	1.0	25
6	Impact of Circulating and Tissue Biomarkers in Adjuvant and Neoadjuvant Therapy for High-Risk Melanoma: Ready for Prime Time?. American Journal of Clinical Dermatology, 2021, 22, 511-522.	3.3	6
7	Prevalence, characteristics, and treatment of fatigue in oncological cancer patients in Italy: a cross-sectional study of the Italian Network for Supportive Care in Cancer (NICSO). Supportive Care in Cancer, 2019, 27, 1041-1047.	1.0	35
8	Efficacy of neurokinin-1 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based chemotherapy: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2018, 124, 21-28.	2.0	15
9	State of the Art of Antiemetic Therapy. , 2018, , 461-480.		0
10	MASCC/ESMO Antiemetic Guidelines: Introduction to the 2016 guideline update. Supportive Care in Cancer, 2017, 25, 267-269.	1.0	19
11	2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy. Supportive Care in Cancer, 2017, 25, 289-294.	1.0	54
12	2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy. Supportive Care in Cancer, 2017, 25, 277-288.	1.0	103
13	2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Annals of Oncology, 2016, 27, v119-v133.	0.6	454
14	Anticipatory Nausea, Risk Factors, and Its Impact on Chemotherapy-Induced Nausea and Vomiting: Results From the Pan European Emesis Registry Study. Journal of Pain and Symptom Management, 2016, 51, 987-993.	0.6	55
15	Chemotherapy-Induced Nausea and Vomiting. BioMed Research International, 2015, 2015, 1-2.	0.9	5
16	A review of olanzapine as an antiemetic in chemotherapy-induced nausea and vomiting and in palliative care patients. Critical Reviews in Oncology/Hematology, 2015, 95, 214-221.	2.0	25
17	Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study. Annals of Oncology, 2015, 26, 1248-1253.	0.6	23
18	Aprepitant Versus Dexamethasone for Preventing Chemotherapy-Induced Delayed Emesis in Patients With Breast Cancer: A Randomized Double-Blind Study. Journal of Clinical Oncology, 2014, 32, 101-106.	0.8	61

FAUSTO ROILA

#	Article	IF	CITATIONS
19	Reply to T.L. Ng et al and L. Celio et al. Journal of Clinical Oncology, 2014, 32, 2187-2188.	0.8	Ο
20	Evaluation of Risk Factors Predicting Chemotherapy-Related Nausea and Vomiting: Results From a European Prospective Observational Study. Journal of Pain and Symptom Management, 2014, 47, 839-848.e4.	0.6	121
21	The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Annals of Oncology, 2012, 23, 1986-1992.	0.6	248
22	Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol—EASE. Journal of Clinical Oncology, 2011, 29, 1495-1501.	0.8	193
23	Acute emesis: moderately emetogenic chemotherapy. Supportive Care in Cancer, 2011, 19, 15-23.	1.0	19
24	Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009. Supportive Care in Cancer, 2011, 19, 37-42.	1.0	46
25	Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only). Supportive Care in Cancer, 2011, 19, 57-62.	1.0	28
26	Prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: Guideline update and results of the Perugia consensus conference. Supportive Care in Cancer, 2011, 19, 63-65.	1.0	22
27	Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Annals of Oncology, 2010, 21, v232-v243.	0.6	585
28	Prevention and treatment of pandemic influenza in cancer patients. Annals of Oncology, 2010, 21, 2301-2303.	0.6	8
29	Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Annals of Oncology, 2010, 21, 1083-1088.	0.6	133
30	The Burden of Chemotherapy Induced Nausea and Vomiting on Patients' Daily Lives: Italian Perspectives. , 2010, , 885-898.		1
31	Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting. Annals of Oncology, 2009, 20, 1867-1873.	0.6	28
32	Chemotherapy-induced nausea and vomiting: ESMO Clinical Recommendations for prophylaxis. Annals of Oncology, 2009, 20, iv156-iv158.	0.6	34
33	Phase III Trial of Casopitant, a Novel Neurokinin-1 Receptor Antagonist, for the Prevention of Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy. Journal of Clinical Oncology, 2009, 27, 5363-5369.	0.8	62
34	Off-label prescription of antineoplastic drugs: an Italian prospective, observational, multicenter survey. Tumori, 2009, 95, 647-51.	0.6	7
35	Chemotherapy-induced nausea and vomiting: ESMO Clinical Recommendations for prophylaxis. Annals of Oncology, 2008, 19, ii110-ii112.	0.6	53
36	New anti-emetic treatments. Annals of Oncology, 2007, 18, ix43-ix47.	0.6	3

FAUSTO ROILA

#	Article	IF	CITATIONS
37	Inappropriate Doses of Chemotherapy in Italian Breast Cancer Patients Enrolled in Clinical Trials. Tumori, 2007, 93, 540-543.	0.6	1
38	The impact of chemotherapy-induced nausea and vomiting on health-related quality of life. Supportive Care in Cancer, 2007, 15, 179-185.	1.0	111
39	Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Annals of Oncology, 2006, 17, 20-28.	0.6	258
40	Daily challenges in oncology practice. What do we need to know about antiemetics?. Annals of Oncology, 2006, 17, x90-x94.	0.6	10
41	Delayed emesis: moderately emetogenic chemotherapy. Supportive Care in Cancer, 2005, 13, 104-108.	1.0	64
42	Acute emesis: moderately emetogenic chemotherapy. Supportive Care in Cancer, 2005, 13, 97-103.	1.0	46
43	Antiemetics in children receiving chemotherapy. Supportive Care in Cancer, 2005, 13, 129-131.	1.0	29
44	Evidence-based recommendations for the use of antiemetics in radiotherapy. Radiotherapy and Oncology, 2005, 76, 227-233.	0.3	46
45	The oral NK1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials. European Journal of Cancer, 2005, 41, 1278-1285.	1.3	127
46	Transferring scientific evidence to oncological practice: a trial on the impact of three different implementation strategies on antiemetic prescriptions. Supportive Care in Cancer, 2004, 12, 446-453.	1.0	34
47	The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group. Journal of Clinical Oncology, 2003, 21, 4112-4119.	0.8	725
48	Delayed emesis: incidence, pattern, prognostic factors and optimal treatment. Supportive Care in Cancer, 2002, 10, 88-95.	1.0	82
49	Is an Antiemetic Prophylactic Treatment Needed for Patients Submitted to Consecutive Days of 5-fluorouracil? An Observational Study. Tumori, 2001, 87, 379-382.	0.6	3
50	Prevention of cisplatin-induced delayed emesis: still unsatisfactory. Supportive Care in Cancer, 2000, 8, 229-232.	1.0	18
51	Optimal selection of antiemetics in children receiving cancer chemotherapy. Supportive Care in Cancer, 1998, 6, 215-220.	1.0	21
52	Prevention of radiotherapy-induced emesis. Tumori, 1998, 84, 274-8.	0.6	6
53	5-HT3 receptor antagonists: Differences and similarities. European Journal of Cancer, 1997, 33, 1364-1370.	1.3	55
54	Delayed emesis induced by moderately emetogenic chemotherapy: Do we need to treat all patients?. Annals of Oncology, 1997, 8, 561-567.	0.6	22

FAUSTO ROILA

#	Article	IF	CITATIONS
55	Comparative studies of various antiemetic regimens. Supportive Care in Cancer, 1996, 4, 270-280.	1.0	23
56	Methodology of trials with antiemetics. Supportive Care in Cancer, 1996, 4, 281-286.	1.0	17
57	Ondansetron Clinical Pharmacokinetics. Clinical Pharmacokinetics, 1995, 29, 95-109.	1.6	140
58	Cost and Cost-Effectiveness Analysis of Ondansetron Versus Metoclopramide Regimensâ€. Pharmacoeconomics, 1994, 5, 227-237.	1.7	21
59	Reducing Chemotherapy-Induced Nausea and Vomiting Current Perspectives and Future Possibilities. Drug Safety, 1993, 9, 410-428.	1.4	51
60	Prevention of Chemotherapy-Induced Emesis: The State of the Art. Digestive Diseases, 1993, 11, 343-353.	0.8	3
61	Double-blind crossover trial of single vs. divided dose of metoclopramide in a combined regimen for treatment of cisplatin-induced emesis. European Journal of Cancer & Clinical Oncology, 1991, 27, 119-121.	0.9	17
62	Intra and interobserver variability in cancer patients' performance status assessed according to Karnofsky and ECOG scales. Annals of Oncology, 1991, 2, 437-439.	0.6	119
63	Predictive Factors of Delayed Emesis in Cisplatin-Treated Patients and Antiemetic Activity and Tolerability of Metoclopramide or Dexamethasone. American Journal of Clinical Oncology: Cancer Clinical Trials, 1991, 14, 238-242.	0.6	106